Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Metformin and Kidney Cancer Outcomes Among Diabetics: a Population Based Cohort Study

EF 2014-15

Résumé
Kidney cancer is a significant cause of cancer mortality in Canada and the incidence of kidney cancer has been rising since 1981. The treatment options for advanced disease or recurrence after treatment are very limited, and the outcomes of patients affected have not improved over time. Given the aggressive nature of kidney cancer, research is needed to identify potential therapies to improve outcomes. Metformin is a medication commonly used to treat diabetes and is relatively inexpensive and well-tolerated. Recently, metformin has gained interest for its anti-cancer properties. Several laboratory and animal studies have demonstrated that metformin inhibits the growth of several cancers. Furthermore, population studies have shown favourable outcomes in users of metformin compared to non-users in various malignancies such as prostate, pancreatic, colorectal, endometrial, ovarian, and breast cancer. Given these promising effects, randomized controlled trials are underway to assess if metformin can improve cancer outcomes even in non-diabetic patients. However, not much is known about the influence of metformin use on patients with kidney cancer. The proposed study will use various Ontario wide patient databases to identify diabetic patients diagnosed with kidney cancer and compare outcomes in users of metformin compared to non-users. The resultshave the potential of furthering our understanding of kidney cancer and highlighting a treatment option to improve outcomes in a cancer that is highly prevalent, increasing in incidence, and often lethal. If this study proves positive, it may provide rationale to proceed with a randomized trial whereby patients undergoing surgery for kidney cancer would start metformin.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
331544
Name
Nayan Madhur
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Metformin and Kidney Cancer Outcomes Among Diabetics: a Population Based Cohort Study
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Diabetes; Kidney Neoplasm; Metformin; Outcomes Research; Recurrence; Surgery; Survival
Abstract
Kidney cancer is a significant cause of cancer mortality in Canada and the incidence of kidney cancer has been rising since 1981. The treatment options for advanced disease or recurrence after treatment are very limited, and the outcomes of patients affected have not improved over time. Given the aggressive nature of kidney cancer, research is needed to identify potential therapies to improve outcomes. Metformin is a medication commonly used to treat diabetes and is relatively inexpensive and well-tolerated. Recently, metformin has gained interest for its anti-cancer properties. Several laboratory and animal studies have demonstrated that metformin inhibits the growth of several cancers. Furthermore, population studies have shown favourable outcomes in users of metformin compared to non-users in various malignancies such as prostate, pancreatic, colorectal, endometrial, ovarian, and breast cancer. Given these promising effects, randomized controlled trials are underway to assess if metformin can improve cancer outcomes even in non-diabetic patients. However, not much is known about the influence of metformin use on patients with kidney cancer. The proposed study will use various Ontario wide patient databases to identify diabetic patients diagnosed with kidney cancer and compare outcomes in users of metformin compared to non-users. The resultshave the potential of furthering our understanding of kidney cancer and highlighting a treatment option to improve outcomes in a cancer that is highly prevalent, increasing in incidence, and often lethal. If this study proves positive, it may provide rationale to proceed with a randomized trial whereby patients undergoing surgery for kidney cancer would start metformin.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nayan, Madhur
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~